|
Match
|
Document |
Document Title |
|
|
US20090291993 |
Difluorophenol Derivatives and Their Use
The present application relates to novel difluorophenol derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing...
|
|
|
US20090291968 |
SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS
Objects of the present invention are the compounds of formula I
their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the...
|
|
|
US20090286827 |
NOVEL BI-ARYL AMINES
The present invention relates to novel bi-aryl amines of formula (I) and to pharmaceutically acceptable prodrugs, salts, solvates, hydrates, and N-oxides thereof and to pharmaceutical compositions...
|
|
|
US20090281155 |
Dimeric Small Molecule Potentiators of Apoptosis
Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent...
|
|
|
US20090275559 |
Chronotherapeutic formulations of modified-release calcium channel blocker anti-hypertensive drugs in combination with other anti-hypertensive drugs for 24-hour optimal treatment of hypertension, nocturnal hypertension, and/or hypertension with angina
The present invention relates to formulations of anti-hypertensive drugs. The present invention includes a modified-release formulation of diltiazem hydrochloride that is suitable for once-daily...
|
|
|
US20090270470 |
Compounds I
Compounds of formula I,
wherein R1, Z, X, Y, M and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical composition containing the same, methods of...
|
|
|
US20090270421 |
INHIBITORS OF FATTY ACID AMIDE HYDROLASE
Potent inhibitors of fatty acid amide hydrolase (FAAH) are constructed having K i 's below 200 pM and activities 10 2 -10 3 times more potent than the corresponding trifluoromethyl ketones. The...
|
|
|
US20090264414 |
Amide Derivatives and Pharmaceutical Use Thereof
The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a...
|
|
|
US20090258919 |
Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failure
The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of...
|
|
|
US20090258918 |
EP4 receptor agonist, compositions and methods thereof
This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which...
|
|
|
US20090258892 |
FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF
The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as...
|
|
|
US20090253664 |
COMBINATION ANDOLAST/GLUCOCORTICOIDS
The invention relates to the combination of Andolast, a calcium-activated potassium channel opener and glucocorticoids for the treatment of patients suffering for airway diseases. Pharmaceutical...
|
|
|
US20090247595 |
Process for the preparation of tetrazolyl compounds
The invention provides a method for preparing candesartan cilexetil and related tetrazolyl compounds. More particularly, the invention relates to the preparation of candesartan cilexetil and...
|
|
|
US20090247591 |
SUBSTITUTED CYCLOHEXYLDIAMINES
The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these...
|
|
|
US20090239865 |
DIBENZYL AMINE COMPOUNDS AND DERIVATIVES
Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density...
|
|
|
US20090238871 |
PHARMACEUTICAL COMPOSITION
A pharmaceutical composition comprising an ester of 4-(1-hydroxy-1-methylethyl)-2 propyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]met
hyl]-1H-imidazole-5-carboxylic acid characterized in...
|
|
|
US20090232886 |
ORAL DOSAGE COMBINATION PHARMACEUTICAL PACKAGING
Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation...
|
|
|
US20090227646 |
Compositions Comprising Nebivolol
Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present...
|
|
|
US20090226516 |
SARTAN COMPOSITIONS
The invention provides a sartan or salt thereof composition having a dissolution in acetate buffer at pH 4.0 using USP type I method basket 10 Mesh at 75 rpm, of at least 20% after 90 minutes, 50%...
|
|
|
US20090220597 |
RAPID RELEASE IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITION
The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one...
|
|
|
US20090215844 |
Compositions Comprising Nebivolol
Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present...
|
|
|
US20090215843 |
Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases
The present application relates to novel tetrazole derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments...
|
|
|
US20090215838 |
ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE
The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing...
|
|
|
US20090215775 |
Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
Compounds of formula (I) are disclosed for treatment of cancer.
|
|
|
US20090208583 |
TABLETS COMPRISING CANDESARTAN CILEXETIL
Composition in the form of a tablet, comprising candesartan cilexetil and optionally further active agents and usual adjuncts, wherein the surface of at least the active agent candesartan cilexetil...
|
|
|
US20090208573 |
NOVEL POLYMORPH FORM OF IRBESARTAN
New form of irbesartan having favourable chargeability is prepared from the alcoholic/etheric or ketonic solution of irbesartan after slow cooling with sporadic or light agitation and alternatively...
|
|
|
US20090203653 |
Compositions and Methods Using Apocynin Compounds and Nitric Oxide Donors
The invention describes novel compositions comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor, and, optionally, at least...
|
|
|
US20090197888 |
FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:
which inhibit serine protease activity, particularly the activity of...
|
|
|
US20090197843 |
Treatment of Prevention of Unscheduled Bleeding in Women on Progestogen Containing Medication
The present invention relates to a method of treating or preventing unscheduled bleeding in women, the unscheduled bleeding being the result of repeated administration of a hormonal composition...
|
|
|
US20090192158 |
Methods for Treating or Preventing Neoplasias
The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits...
|
|
|
US20090192119 |
Inhibition of the Renin-Angiotensin System for the Treatment of Renal, Vascular and Cartilage Pathology
A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically...
|
|
|
US20090186895 |
ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical...
|
|
|
US20090176848 |
FORTIFIER
An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost...
|
|
|
US20090176841 |
NOVEL 6-5 SYSTEM BICYCLIC HETEROCYCLIC DERIVATIVE AND ITS PHARMACEUTICAL UTILITY
An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The...
|
|
|
US20090176831 |
Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System
Disclosed are compounds of the general formula (I):
compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods...
|
|
|
US20090176804 |
2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
The present invention is directed to 2-phenyl-indole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient...
|
|
|
US20090176773 |
Non-Peptidic Inhibitors of AKAP/PKA Interaction
The invention relates to non-peptidic molecules which modulate, especially inhibit, the interaction of protein kinase A (PKA) and A kinase anchor proteins (AKAP) and to a host or target organism...
|
|
|
US20090170917 |
Acid Mimic Compounds for the Inhibition of Isoprenyl-S-Cysteinyl Methyltransferase
Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and...
|
|
|
US20090170908 |
SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF
The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof
|
|
|
US20090170842 |
BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE
A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically...
|
|
|
US20090170832 |
HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula:
a pharmaceutically acceptable salt or solvate thereof, wherein R 1 ...
|
|
|
US20090163502 |
Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists
Compounds of the formula I:
or a pharmaceutically acceptable salt thereof, wherein, R 1 is optionally substituted tetrazolyl, R 2 is optionally substituted phenyl, optionally substituted...
|
|
|
US20090156655 |
GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods...
|
|
|
US20090156585 |
ORGANIC COMPOUNDS
A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension.
|
|
|
US20090149521 |
DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS
The invention relates to compounds having the formula:
wherein Ar, r, n, X, R 2 , R 2′ , R 3 , and R 5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof....
|
|
|
US20090137648 |
PROCESS FOR THE PREPARATION OF IRBESARTAN HYDROCHLORIDE
The present invention is concerned with a process for the preparation of 2n-butyl-4-spirocyclopentane-1-[(2′-(tetrazol-5-yl)bipheny
l-4-yl)methyl]-2-imidazolin-5-one hydrochloride, irbesartan...
|
|
|
US20090136571 |
PHARMACEUTICAL FORMULATIONS CONTAINING IRBESARTAN
The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally...
|
|
|
US20090130117 |
Substituted Tetrazole Compounds and Uses Thereof
The present invention provides tetrazole compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the tetrazole...
|
|
|
US20090124677 |
Method For Obtaining A Pharmaceutically Active Compound (Irbesartan) And Its Synthesis Intermediate
It is provided a method for obtaining Irbesartan polymorph A, with few synthesis steps, by coupling the intermediate of formula (II) with the compound of formula (III), neutralising one of its...
|
|
|
US20090124669 |
Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders
Novel compounds for the prevention and treatment of dermatological disorders with an immunoallergic, hyperproliferative and inflammatory component, and a method of producing such compounds. The...
|